-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Introduction: Pythatan hydrochlorophenic tablet adaptation: treatment of a single drug can not fully control blood pressure of mild-moderate primary hypertension.
. On September 15, China Resources Shuanghe announced that its wholly-owned subsidiary, China Resources Seko Pharmaceutical Co., Ltd., had received a "Notice of Approval of Drug Supplemental Application" issued by the State Drug Administration for the approval of the drug through the quality and efficacy of generic drugs.
: Treatment of mild-moderate primary hypertension that does not adequately control blood pressure with a single drug.
China Resources Seko initiated the consistency evaluation of the drug in November 2017, submitted a conformity evaluation application to the State Drug Administration on November 5, 2019, received a notice of acceptance on November 20, 2019, and approved it by the State Drug Administration on September 3, 2020, and is the second company to pass the drug consistency evaluation.
date of this announcement, China Resources Seko has invested RMB17.2533 million (unaudited) in research and development for the consistent evaluation of the drug.
was first developed by Novartis Pharma Schweiz AG in Switzerland and was approved by the FDA in 1998 to be listed in the United States under the name DIOVAN HCT ®.
the U.S., the main producers of Pyrochlorophenidate are NOVORTIS, AUROBINDO PHARMA LTD, LUPIN LTD, etc., and the Diovan Group has annual global sales of $1,064 million, according to the 2019 annual report released by Novartis Pharmaceuticals of Switzerland.
chinese company, was launched in China in 2005 and the imported drug manufacturer is Novortis Farma S.p.A. (I), with the trade name "Fudaiwen".
According to data from Guangdong Punctuation Pharmaceutical Information Co., Ltd., a subsidiary of the Southern Institute of Pharmaceutical Economics, the total sales of pyridoxine tablets in The Chinese market in 2019 amounted to RMB1.15 billion;
2019, China Resources Seko's sales revenue from the drug was RMB13,146.27 million (audited).
.